StepChange Innovations blog covers innovations and issues in pharma
Indian government forces Bayer to accept generic Nexavar competition – FiercePharma
India has invoked its compulsory licensing rules for the first time to make and sell a version of Bayer's cancer drug Nexavar despite the fact that Nexavar is still on patent. We think this is quite a significant development. What does it mean for ROI of big pharma companies R&D ? What does it mean for IP integrity for doing business in India ? Continue reading
Controlling protein function with nanotechnology
A new study provides important details on how proteins in our bodies interact with nanomaterials. Continue reading
In the genes, but which ones?
Studies that linked specific genes to intelligence were largely wrong, experts say. Continue reading